EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dupilumab’s Impact on Blood Parameters in Nasal Polyposis: 18-Month Follow-Up in Real Life

Antonella Loperfido iD, Andrea Ciofalo, Carlo Cavaliere iD, Elona Begvarfaj iD, Francesca Cascone, Giacomo Alfonzo, Rosalba Cadeddu, Stefano Millarelli, Gianluca Bellocchi iD, Antonio Greco iD, Marco de Vincentiis, Simonetta Masieri iD

Journal of Immunology Research · 15.09.2023 · 2023 · 1-10

DOI: 10.1155/2023/4027701 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Immunology Research, erschienen am 15.09.2023. Verfasst von Antonella Loperfido und 11 weiteren Autor:innen. Beteiligte Einrichtung: Otolaryngology Unit, San Camillo Forlanini Hospital, Rome, Italy. Hauptthemen laut MEDLINE: Nasal Polyps. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dupilumab represents the first approved biological for severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP).

Objective

Aim of this paper is to provide a multicentric real-life study about treatment with dupilumab for CRSwNP with a special focus on blood parameters and IgE, IgG, and IgA.

Method

A retrospective data collection was jointly conducted at the Otolaryngology departments of San Camillo Forlanini Hospital and University of Rome “La Sapienza” from December 2020 to January 2023.

Results

A total of 130 patients were included in the study. Monitoring our patients for 18 months, we observed a reduction in nasal polyposis and an improvement in symptoms and their impact on quality of life. Regarding blood tests, a transient increase in blood eosinophils was found in most cases. Total IgE showed a gradual decrease in values. IgG and IgA also showed a slight reduction of values, while remaining within normal ranges.

Conclusion

To the best of our knowledge, this is the first study to evaluate the impact of dupilumab on several blood parameters in patients receiving treatment for CRswNP. Further studies are needed to confirm our results and to understand the underlying immunological mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nasal PolypsHumansFollow-Up StudiesQuality of LifeRetrospective StudiesImmunoglobulin AImmunoglobulin EImmunoglobulin GAntibodies, Monoclonal, Humanized

Substanzen

Immunoglobulin AImmunoglobulin EImmunoglobulin GdupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Otolaryngology Unit, San Camillo Forlanini Hospital, Rome, Italy.
  • Department of Sense Organs, Sapienza University, Rome, Italy.
  • Department of Oral and Maxillofacial Sciences, Sapienza University, Rome, Italy.

ORCID-Profile: Antonella Loperfido, Carlo Cavaliere, Elona Begvarfaj, Gianluca Bellocchi, Antonio Greco, Simonetta Masieri

Zitieren

APA

Loperfido, A., Ciofalo, A., Cavaliere, C., Begvarfaj, E., Cascone, F., Alfonzo, G., Cadeddu, R., Millarelli, S., Bellocchi, G., Greco, A., de Vincentiis, M., & Masieri, S. (2023). Dupilumab’s Impact on Blood Parameters in Nasal Polyposis: 18-Month Follow-Up in Real Life. Journal of Immunology Research, 2023, 1-10. https://doi.org/10.1155/2023/4027701

Vancouver

Loperfido A, Ciofalo A, Cavaliere C, Begvarfaj E, Cascone F, Alfonzo G, et al. Dupilumab’s Impact on Blood Parameters in Nasal Polyposis: 18-Month Follow-Up in Real Life. Journal of Immunology Research. 2023;2023:1-10. doi:10.1155/2023/4027701

BibTeX
@article{Loperfido2023,
  author = {Loperfido, Antonella and Ciofalo, Andrea and Cavaliere, Carlo and Begvarfaj, Elona and Cascone, Francesca and Alfonzo, Giacomo and Cadeddu, Rosalba and Millarelli, Stefano and Bellocchi, Gianluca and Greco, Antonio and de Vincentiis, Marco and Masieri, Simonetta},
  title = {Dupilumab’s Impact on Blood Parameters in Nasal Polyposis: 18-Month Follow-Up in Real Life},
  journal = {Journal of Immunology Research},
  year = {2023},
  volume = {2023},
  pages = {1--10},
  doi = {10.1155/2023/4027701}
}
Kostenlos starten →